Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Taxes: 2013-2024

Historic Change in Taxes for Ani Pharmaceuticals (ANIP) over the last 12 years, with Dec 2024 value amounting to -$1.4 million.

  • Ani Pharmaceuticals' Change in Taxes fell 287.64% to -$12.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 million, marking a year-over-year increase of 53.01%. This contributed to the annual value of -$1.4 million for FY2024, which is 111.80% down from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Change in Taxes of -$1.4 million as of FY2024, which was down 111.80% from $12.0 million recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Change in Taxes high stood at $12.0 million for FY2023, and its period low was -$7.6 million during FY2021.
  • Its 3-year average for Change in Taxes is $3.5 million, with a median of -$160,000 in 2022.
  • Its Change in Taxes has fluctuated over the past 5 years, first plummeted by 252.01% in 2021, then soared by 7,594.37% in 2023.
  • Over the past 5 years, Ani Pharmaceuticals' Change in Taxes (MRY) stood at $5.0 million in 2020, then crashed by 252.01% to -$7.6 million in 2021, then soared by 97.89% to -$160,000 in 2022, then soared by 7,594.37% to $12.0 million in 2023, then plummeted by 111.80% to -$1.4 million in 2024.
  • Its last three reported values are -$1.4 million in FY2024, $12.0 million for FY2023, and -$160,000 during FY2022.